HTA Database - Search Results

Sort by Relevance

Search Results [15895 Hits] Selected Records [0 Hits] [Clear]

Year	Source	Title
2019	European Network for Health Technology Assessment (EUnetHTA)	Bioresorbable stents for the treatment of cardiovascular indications (coronary artery disease)
2019	European Network for Health Technology Assessment (EUnetHTA)	Lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH)
2019	European Network for Health Technology Assessment (EUnetHTA)	Regional hyperthermia for high-risk soft tissue sarcoma treatment
2019	European Network for Health Technology Assessment (EUnetHTA)	Screening for osteoporosis in the general population
2019	European Network for Health Technology Assessment (EUnetHTA)	Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)
2019	European Network for Health Technology Assessment (EUnetHTA)	Point-of-care tests (POCT): D-dimer and troponin
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Canagliflozin, empagliflozin and dapagliflozin in type 2 diabetes patients]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Bevacizumab in age-related macular degeneration]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Thiazolidinediones for type 2 diabetes mellitus]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Canagliflozin, empagliflozin and dapagliflozin (SGLT-2) for patients with type 2 diabetes]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Pirfenidone in pulmonary fibrosis]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Hyaluronic acid dermal fillers in skin repair procedures]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Alirocumab for patients with hypercholesterolemia]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[PET-CT in patients with head and neck cancer diagnosis]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Relex® SMILE® surgery for refractive errors]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Liraglutide in obese and overweight patients]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Respiratory polygraphy for obstructive sleep apnea syndrome]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Thiazolidinediones for type 2 diabetes mellitus]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Positron-emission tomography for breast cancer]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intra-articular hyaluronic acid (viscosupplementation) for osteoarthritis]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Kinanthropometric nutritional assessment]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[High frequency chest compression vest for ambulatory pulmonary physical therapy in patients with cystic fibrosis]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Cerliponase alfa in neuronal ceroid lipofuscinosis type 2]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Prolotherapy in chronic musculoskeletal disorders]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Percutaneous cement discoplasty for the treatment of degenerative scoliosis in the elderly]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Shear-wave elastography for liver fibrosis]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Bendamustine as first line therapy for indolent non-Hodgkin’s lymphoma]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Erenumab in migraine prevention]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[4CMenB vaccine for primary vaccination]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Teriparatide in biphosphonate-resistant osteoporosis and high fracture risk]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Immunocyanin in urothelial bladder cancer
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Central auditory processing disorder diagnosis]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Selexipag in pulmonary hypertension]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Holmium laser enucleation in benign prostatic hyperplasia]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[No-scalpel versus conventional vasectomy]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Quantitative electroencephalography]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Reiki therapy in anxiety, depression and pain]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Hip arthroscopy for painful hip treatment]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Prostate rectum spacing in prostate radiation therapy]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Endovascular thrombectomy in acute ischemic stroke]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Deep anterior lamellar keratoplasty in keratoconus]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Shoulder prosthesis in complex proximal humeral fractures]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Implantable cardiac monitors in syncope of unknown etiology]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Rapid on-site evaluations of cytological punctures]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Per-oral endoscopic myotomy (POEM) in achalasia]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Optical coherence tomography: usefulness in glaucoma, diabetic retinopathy and age-related macular degeneration]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Video head impulse test in vertigo]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Palivizumab for the prevention of respiratory syncytial virus lower respiratory tract infections]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Sacral nerve stimulation/neuromodulation in bladder and/or bowel incontinence]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Eposterior tibial nerve stimulation in overactive bladder and bowel incontinence]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Pelvic vein embolization or sclerotherapy in pelvic congestion syndrome]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Lenvatinib for iodine-refractory differentiated thyroid cancer]
2019	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[Identification of psychosocial practices and interventions that support the adaptation and rehabilitation of adults with Prader-Willi Syndrome]
2019	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Effectiveness and safety of epicardial closure of left atrial appendage using clips by minimally invasive surgery for thromboembolism prevention in patients with atrial fibrillation]
2019	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Validity, clinical utility and safety of the next-generation sequencing (NGS) genomic platform FoundationOne® in non-small cell lung cancer and other solid tumors]
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Axicabtagene ciloleucel (PMBCL)]
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Bedaquiline (assessment of an orphan drug after exceeding the turnover limit of €1 million)]
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive (AM-RL): Annex XII – Benefit assessment of medicinal products with new active ingredients according to section 35a SGB V brentuximab vedotin (new therapeutic indication: Hodgkin lymphoma, first line)]
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Caplacizumab (New Therapeutic Indication: Acquired Thrombotic Thrombocytopenic Purpura, 12 to < 18 Years)]
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Glycerol phenylbutyrate (New Therapeutic Indication: Urea cycle disorders in infants aged 0 to < 2 months)]
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ixazomib]
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Mexiletine]
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Pegvaliase]
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Voretigene Neparvovec]
2019	Canadian Agency for Drugs and Technologies in Health (CADTH)	Tisagenlecleucel for acute lymphoblastic leukemia and diffuse large b-cell lymphoma: clinical report
2019	Canadian Agency for Drugs and Technologies in Health (CADTH)	Optimal use of minimally invasive glaucoma surgery: a health technology assessment
2019	Canadian Agency for Drugs and Technologies in Health (CADTH)	Dual antiplatelet therapy following percutaneous coronary intervention: clinical and economic impact of standard versus extended duration
2019	Canadian Agency for Drugs and Technologies in Health (CADTH)	Community water fluoridation programs: a health technology assessment - review of dental caries and other health outcomes
2019	Canadian Agency for Drugs and Technologies in Health (CADTH)	HPV testing for primary cervical cancer screening: a health technology assessment
2019	Canadian Agency for Drugs and Technologies in Health (CADTH)	Internet-delivered cognitive behavioural therapy for major depressive disorder and anxiety disorders: a health technology assessment
2019	Canadian Agency for Drugs and Technologies in Health (CADTH)	Axicabtagene ciloleucel for large B-cell lymphoma: clinical report
2019	Canadian Agency for Drugs and Technologies in Health (CADTH)	Genome-wide sequencing: ethical considerations
2019	Canadian Agency for Drugs and Technologies in Health (CADTH)	Flash glucose monitoring system for people with type 1 or type 2 diabetes: a health technology assessment
2019	Canary Health Service	[Cost-effectiveness of mechanical thrombectomy for treatment of ischaemic stroke]
2019	Andalusian Health Technology Assessment Area (AETSA)	[Blood test for the early diagnosis of pancreatic cancer. CancerSEEK]
2019	Andalusian Health Technology Assessment Area (AETSA)	[Post-introduction observational study of predictive/prognostic tests in breast cancer of the Andalusian Public Health System (SSPA)]
2019	Agency for Care Effectiveness (ACE)	Video capsule endoscopy for diagnosing obscure gastrointestinal bleeding
2019	Agency for Care Effectiveness (ACE)	Ambulatory sleep study for diagnosing obstructive sleep apnoea
2019	Agency for Care Effectiveness (ACE)	Botulinum toxin A for the management of focal spasticity of the upper limbs associated with stroke in adults
2019	Agency for Care Effectiveness (ACE)	Ticagrelor for preventing thrombotic events in adults with acute coronary syndromes
2019	Agency for Care Effectiveness (ACE)	Nintedanib and pirfenidone for treating idiopathic pulmonary fibrosis
2019	Agency for Care Effectiveness (ACE)	Daptomycin and linezolid for treating vancomycin-resistant enterococci bloodstream infections
2019	Agency for Care Effectiveness (ACE)	Omalizumab for treating antihistamine-resistant chronic spontaneous urticaria
2019	Agency for Care Effectiveness (ACE)	Vedolizumab for treating ulcerative colitis and Crohn's disease
2019	Agency for Care Effectiveness (ACE)	Febuxostat for treating chronic hyperuricaemia in adults with gout
2019	Agency for Care Effectiveness (ACE)	Ezetimibe and ezetimibe/simvastatin for treating primary hypercholesterolaemia
2019	Agency for Care Effectiveness (ACE)	Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy
2019	Agency for Care Effectiveness (ACE)	Botulinum toxin A for treating blepharospasm or hemifacial spasm
2019	Agency for Care Effectiveness (ACE)	Oral COX-2 inhibitors for treating pain
2019	Agency for Care Effectiveness (ACE)	Ferric carboxymaltose for treating iron deficiency anaemia
2019	Agency for Care Effectiveness (ACE)	Botulinum toxin A for treating cervical dystonia
2019	Agency for Care Effectiveness (ACE)	Botulinum toxin A for treating focal spasticity of the upper or lower limbs in children with cerebral palsy
2019	Agency for Care Effectiveness (ACE)	Endothelin receptor antagonists for treating pulmonary arterial hypertension
2019	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	Medicinsk teknologivurdering (MTV) af HPV vaccination til drenge
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lenvatinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ocriplasmin (vitreomacular traction, including when associated with macular hole) - Benefit assessment according to §35a Social Code Book V (reassessment after expiry of the decision)]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (head and neck squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Negative pressure wound therapy for wounds healing by secondary intention]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ingenol mebutate (actinic keratosis) - Addendum to Commission A18-55]